VBI-2901 / VBI Vaccines - LARVOL DELTA

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering (Businesswire) - "VBI Vaccines Inc...today announced the pricing of its previously announced underwritten public offering of 10,909,091 common shares and accompanying common warrants to purchase up to 10,909,091 common shares, and its concurrent registered direct offering of 1,818,182 common shares and accompanying common warrants to purchase up to 1,818,182 common shares, at a combined public offering price of $1.65 per share and accompanying common warrant...The offerings are expected to close on or about July 10, 2023, subject to satisfaction of customary closing conditions...VBI intends to use the net proceeds from both offerings for the commercialization activities for PreHevbrio® [Hepatitis B Vaccine (Recombinant)] in the United States, Europe, and Canada; manufacturing of PreHevbrio and clinical materials for its pipeline programs; and ongoing activities related to its development stage candidates, including VBI-1901 (glioblastoma) and VBI-2901 (coronaviruses)."

Commercial • Pricing • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Hepatitis B • Novel Coronavirus Disease • Oncology • Solid Tumor

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants (Businesswire) - "VBI Vaccines...announced that it has commenced an underwritten public offering and a registered direct offering of its common shares and accompanying common warrants to purchase its common shares....VBI intends to use the net proceeds from both offerings for the commercialization activities for PreHevbrio® [Hepatitis B Vaccine (Recombinant)] in the United States, Europe, and Canada; manufacturing of PreHevbrio and clinical materials for its pipeline programs; and ongoing activities related to its development stage candidates, including VBI-1901 (glioblastoma) and VBI-2901 (coronaviruses)."

Financing • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Hepatitis B • Infectious Disease • Novel Coronavirus Disease • Oncology • Solid Tumor

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: VBI Vaccines Inc. | N=60 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a (clinicaltrials.gov) - P1 | N=103 | Active, not recruiting | Sponsor: VBI Vaccines Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: VBI Vaccines Inc. | Initiation date: Nov 2022 ➔ Mar 2023

Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: VBI Vaccines Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a (clinicaltrials.gov) - P1 | N=99 | Recruiting | Sponsor: VBI Vaccines Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a (clinicaltrials.gov) - P1 | N=99 | Not yet recruiting | Sponsor: VBI Vaccines Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

VBI Vaccines Announces Progress of Coronavirus Vaccine Program (Businesswire) - "VBI Vaccines Inc....provided an update on the progress of its coronavirus vaccine program...The protective efficacy of VBI-2902, with two different adjuvant formulations, was assessed in hamsters where SARS-CoV-2 infection resembles features found in humans with moderate COVID-19 infection and is characterized by a rapid weight loss starting two days post infection....VBI expects to initiate the first Phase 1/2 clinical study of VBI-2902 in Canada in Q1 2021....Work is ongoing to further optimize and manufacture the Company’s pan-coronavirus vaccine candidate, VBI-2901, with the anticipation that a Phase 1/2 study will begin later in 2021."

New P1/2 trial • Preclinical • Infectious Disease • Novel Coronavirus Disease

"My Three Biotech Covid-19 Stocks: Inovio Pharmaceuticals (INO), iBio (IBIO), and VBI Vaccines (VBIV) https://t.co/TguUozFZH5" (@alliseeis_W)

Infectious Disease • Novel Coronavirus Disease

VBI Vaccines to Present at Upcoming Scientific Conferences (Businesswire) - “World Vaccine Congress: COVID-19 panel discussion, two oral presentations highlighting...VBI-1901 Phase 1/2a data; VBI Vaccines Inc…announced upcoming presentations highlighting data from multiple clinical programs…VBI-2900, the company’s coronavirus vaccine program; and VBI-1901, the company’s cancer vaccine immunotherapeutic – at the World Vaccine Congress Washington 2020 and ID Week 2020™."

Clinical • P1/2 data • Glioblastoma • Infectious Disease • Novel Coronavirus Disease • Oncology

VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development (Businesswire) - "Variation Biotechnologies Inc....today announced that it has been awarded up to a CAD$56 million contribution from the Strategic Innovation Fund of the Government of Canada to support...VBI-2900, through Phase 2 clinical studies....'This funding will help accelerate our vaccine candidates into and through clinical development, the first clinical studies for which are expected to initiate by the end of 2020'....VBI expects to select the optimal vaccine candidates in the third quarter of 2020 to enable the start of clinical studies by the end of 2020."

Financing • New trial • Infectious Disease • Novel Coronavirus Disease